Company intelligence / Profile preview

Changchun Huapu Biotechnology

Ownership: Private
Development stage: Other

Overview

HP007 (TLR9 agonist) has achieved IND approval for advanced cancer in China. FS-8002 (TGF-β x VEGF bispecific) is in a Phase 1 trial in advanced malignant solid tumors. HP-06T07, a TLR9 agonist, is in preclinical development for colonic cancer. No completed clinical results are published as of July 2025.

Therapeutic areas: Oncology
Modalities: OligonucleotideAntibody fusion proteinsCpG ODNProphylactic vaccineGenetically engineered subunit vaccine
Industry: Biotech

Drug pipeline

2 assets

FS-8002

1 more asset in the full pipeline.

Partnerships

SBI BiotechWalvax BiotechnologyChangsheng Bio-Technology

Beyond the preview

Go deeper on Changchun Huapu Biotechnology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Changchun Huapu Biotechnology.